2014-2023年治疗阿尔茨海默病药物的全球专利格局。

IF 2.2 3区 医学 Q3 CLINICAL NEUROLOGY
Yan Xu, Yuan Gao
{"title":"2014-2023年治疗阿尔茨海默病药物的全球专利格局。","authors":"Yan Xu, Yuan Gao","doi":"10.1186/s12883-025-04352-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's Disease (AD) is a complex neurodegenerative disorder lacking a definitive cure, spurring global efforts to develop effective therapeutic agents. Patent data can provide critical insights into research investments, innovation trends, and market dynamics.</p><p><strong>Objective: </strong>This study offers a comprehensive ten-year overview (2014-2023) of granted AD drug patents, focusing on patent families (A 'patent family' refers to a set of patents or patent applications in different jurisdictions claiming priority to the same original invention. In contrast, a 'patent' typically denotes a single jurisdiction-specific grant. When we aggregate data by families, we seek to avoid double-counting the same invention filed in multiple regions and to measure an invention's overall global protection strategy.) to consolidate international filings for the same invention. By highlighting top assignees, citation impact, and molecular targets, we aim to clarify current R&D directions and identify emerging opportunities in AD drug development.</p><p><strong>Methods: </strong>We extracted 2,088 AD drug patent families from the IncoPat database using International Patent Classification (IPC) codes (A61K, A61P) and keyword searches (\"Alzheimer\" or \"Alzheimer's disease\"). We excluded irrelevant items (e.g., test reagents) and concentrated on legally granted patents to ensure reliable and enforceable innovations. Geographic layouts, applicant rankings, and citation analyses were conducted to reveal innovation hotspots and high-impact patents.</p><p><strong>Result: </strong>Annual granted patent volumes remained stable until a slight decline after 2021. While large pharmaceutical companies (e.g., Hoffmann-La Roche) dominated in terms of total patent families, several highly cited patents originated from smaller or less prolific applicants, reflecting unique or foundational breakthroughs. The United States led in patent counts, yet notable growth was seen in China and other emerging markets. Small-molecule compounds (including isoindoline derivatives) and monoclonal antibodies were predominant targets, though gene therapy and neuroinflammation-focused patents also gained traction.</p><p><strong>Conclusions: </strong>Our findings highlight how AD patent landscapes integrate multiple scientific pathways and commercial strategies. The discrepancy between top patentees and top-cited inventions underscores the multifaceted nature of innovation in AD therapeutics. These insights, combined with broader scientific context, may guide policy decisions, R&D collaborations, and future research priorities in tackling this urgent healthcare challenge.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"25 1","pages":"361"},"PeriodicalIF":2.2000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382284/pdf/","citationCount":"0","resultStr":"{\"title\":\"The global patent landscape of the drugs for treating Alzheimer's disease from 2014-2023.\",\"authors\":\"Yan Xu, Yuan Gao\",\"doi\":\"10.1186/s12883-025-04352-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Alzheimer's Disease (AD) is a complex neurodegenerative disorder lacking a definitive cure, spurring global efforts to develop effective therapeutic agents. Patent data can provide critical insights into research investments, innovation trends, and market dynamics.</p><p><strong>Objective: </strong>This study offers a comprehensive ten-year overview (2014-2023) of granted AD drug patents, focusing on patent families (A 'patent family' refers to a set of patents or patent applications in different jurisdictions claiming priority to the same original invention. In contrast, a 'patent' typically denotes a single jurisdiction-specific grant. When we aggregate data by families, we seek to avoid double-counting the same invention filed in multiple regions and to measure an invention's overall global protection strategy.) to consolidate international filings for the same invention. By highlighting top assignees, citation impact, and molecular targets, we aim to clarify current R&D directions and identify emerging opportunities in AD drug development.</p><p><strong>Methods: </strong>We extracted 2,088 AD drug patent families from the IncoPat database using International Patent Classification (IPC) codes (A61K, A61P) and keyword searches (\\\"Alzheimer\\\" or \\\"Alzheimer's disease\\\"). We excluded irrelevant items (e.g., test reagents) and concentrated on legally granted patents to ensure reliable and enforceable innovations. Geographic layouts, applicant rankings, and citation analyses were conducted to reveal innovation hotspots and high-impact patents.</p><p><strong>Result: </strong>Annual granted patent volumes remained stable until a slight decline after 2021. While large pharmaceutical companies (e.g., Hoffmann-La Roche) dominated in terms of total patent families, several highly cited patents originated from smaller or less prolific applicants, reflecting unique or foundational breakthroughs. The United States led in patent counts, yet notable growth was seen in China and other emerging markets. Small-molecule compounds (including isoindoline derivatives) and monoclonal antibodies were predominant targets, though gene therapy and neuroinflammation-focused patents also gained traction.</p><p><strong>Conclusions: </strong>Our findings highlight how AD patent landscapes integrate multiple scientific pathways and commercial strategies. The discrepancy between top patentees and top-cited inventions underscores the multifaceted nature of innovation in AD therapeutics. These insights, combined with broader scientific context, may guide policy decisions, R&D collaborations, and future research priorities in tackling this urgent healthcare challenge.</p>\",\"PeriodicalId\":9170,\"journal\":{\"name\":\"BMC Neurology\",\"volume\":\"25 1\",\"pages\":\"361\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382284/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12883-025-04352-9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12883-025-04352-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:阿尔茨海默病(AD)是一种复杂的神经退行性疾病,缺乏明确的治疗方法,促使全球努力开发有效的治疗药物。专利数据可以为研究投资、创新趋势和市场动态提供重要见解。目的:本研究提供了10年(2014-2023年)已授予的AD药物专利的全面概述,重点关注专利族(“专利族”是指在不同司法管辖区对同一原始发明要求优先权的一组专利或专利申请)。相比之下,“专利”通常是指单一的特定司法管辖区的授权。当我们按家庭汇总数据时,我们力求避免重复计算在多个地区提交的同一项发明,并衡量一项发明的总体全球保护战略,以合并同一发明的国际申请。通过重点介绍顶级受让人、引文影响和分子靶点,我们旨在阐明当前的研发方向,并确定阿尔茨海默病药物开发的新兴机会。方法:采用国际专利分类(IPC)代码(A61K、A61P)和关键词搜索(“Alzheimer”或“Alzheimer’s disease”),从IncoPat数据库中提取2088个AD药物专利家族。我们排除了不相关的项目(例如,测试试剂),并专注于合法授予的专利,以确保可靠和可执行的创新。通过地理布局、申请人排名和引文分析,揭示创新热点和高影响力专利。结果:年度授权专利量保持稳定,2021年后略有下降。虽然大型制药公司(如霍夫曼-罗氏)在专利族总数上占主导地位,但一些高引用专利来自规模较小或不那么多产的申请人,反映了独特或基础的突破。美国在专利数量上领先,但中国和其他新兴市场也出现了显著增长。小分子化合物(包括异吲哚啉衍生物)和单克隆抗体是主要的目标,尽管基因治疗和以神经炎症为重点的专利也获得了关注。结论:我们的研究结果突出了AD专利景观如何整合多种科学途径和商业策略。顶级专利权人与被引用最多的发明之间的差异凸显了阿尔茨海默病治疗创新的多面性。这些见解与更广泛的科学背景相结合,可以指导政策决策、研发合作和未来的研究重点,以应对这一紧迫的医疗保健挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The global patent landscape of the drugs for treating Alzheimer's disease from 2014-2023.

The global patent landscape of the drugs for treating Alzheimer's disease from 2014-2023.

The global patent landscape of the drugs for treating Alzheimer's disease from 2014-2023.

The global patent landscape of the drugs for treating Alzheimer's disease from 2014-2023.

Background: Alzheimer's Disease (AD) is a complex neurodegenerative disorder lacking a definitive cure, spurring global efforts to develop effective therapeutic agents. Patent data can provide critical insights into research investments, innovation trends, and market dynamics.

Objective: This study offers a comprehensive ten-year overview (2014-2023) of granted AD drug patents, focusing on patent families (A 'patent family' refers to a set of patents or patent applications in different jurisdictions claiming priority to the same original invention. In contrast, a 'patent' typically denotes a single jurisdiction-specific grant. When we aggregate data by families, we seek to avoid double-counting the same invention filed in multiple regions and to measure an invention's overall global protection strategy.) to consolidate international filings for the same invention. By highlighting top assignees, citation impact, and molecular targets, we aim to clarify current R&D directions and identify emerging opportunities in AD drug development.

Methods: We extracted 2,088 AD drug patent families from the IncoPat database using International Patent Classification (IPC) codes (A61K, A61P) and keyword searches ("Alzheimer" or "Alzheimer's disease"). We excluded irrelevant items (e.g., test reagents) and concentrated on legally granted patents to ensure reliable and enforceable innovations. Geographic layouts, applicant rankings, and citation analyses were conducted to reveal innovation hotspots and high-impact patents.

Result: Annual granted patent volumes remained stable until a slight decline after 2021. While large pharmaceutical companies (e.g., Hoffmann-La Roche) dominated in terms of total patent families, several highly cited patents originated from smaller or less prolific applicants, reflecting unique or foundational breakthroughs. The United States led in patent counts, yet notable growth was seen in China and other emerging markets. Small-molecule compounds (including isoindoline derivatives) and monoclonal antibodies were predominant targets, though gene therapy and neuroinflammation-focused patents also gained traction.

Conclusions: Our findings highlight how AD patent landscapes integrate multiple scientific pathways and commercial strategies. The discrepancy between top patentees and top-cited inventions underscores the multifaceted nature of innovation in AD therapeutics. These insights, combined with broader scientific context, may guide policy decisions, R&D collaborations, and future research priorities in tackling this urgent healthcare challenge.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMC Neurology
BMC Neurology 医学-临床神经学
CiteScore
4.20
自引率
0.00%
发文量
428
审稿时长
3-8 weeks
期刊介绍: BMC Neurology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of neurological disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信